Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Nevro Corporation

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Nevro Corporation

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Nevro Corporation. 2 entries are PMA supplements. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 15, 2025 to Aug 18, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LGW appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P130022, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 1800 Bridge Pkwy., Redwood City, CA, 94065. Recorded on P130022/S069, decision dated Aug 18, 2026.

Changes described in PMA records

P130022/S069: HFX Dynamis System

FDA’s recorded scope: This supplement (S069) requested approval for the next generation implantable pulse generator system referred to as the HFX Dynamis System. The HFX Dynamis System is designed to deliver a new stimulation therapy, Bolus 10kHz, and support expanded MRI access to allow for scanning with one broken conductor per percutaneous lead. The key changes approved in this supplement include: a new Implantable Pulse Generator model (IPG3500), an updated Patient Application (PTA10043, v3.0.0), and updated Clinician Programmer Software (v4.0). The device, as modified, will be marketed under the trade name HFX Dynamis System and is indicated as follows:The HFX Dynamis System, HFX iQ System and HFX Trial System are indicated as aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain, and leg pain. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic neuropathy. The HFX Dynamis System, HFX iQ System and HFX Trial System, when programmed to include a frequency of 10 kHz, are indicated as aids in the management of non-surgical refractory back pain (intractable back pain without prior surgery and not a candidate for back surgery). FDA's review of this PMA supplement also included the review and approval of a PCCP: Juno Predetermined Change Control Plan, Rev A., which includes two future firmware modifications: 1. Disabling the 1 MHz ASIC clock while in MRI Mode for the IPG3000 and IPG3500, to reduce RF artifacts in MRI images; and 2. Optimizing power consumption for bolus therapy programs by disabling the ASIC during the bolus Macro Off Time, applicable to the IPG3500 only.

Aug 18, 2026 · Normal 180 Day Track

P130022/S067: Senza HFX iQ System

FDA’s recorded scope: Approval for changes to the printed circuit board assembly (PCBA) board used in IPG3000, including replacing the microcontroller from rev 2 to rev 3, replacing the fuel gauge with a battery voltage measurement circuit, changing the material of the printed circuit board (PCB), moving the PCBA battery fuse from the negative terminal to the positive terminal, other minor modifications to PCB layout (reorganizing components and modification of solder pad size), as well as an alternate PCBA supplier for IPG3000.

Aug 15, 2025 · Normal 180 Day Track

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
HFX Dynamis SystemP130022/S069
Nevro CorporationPMA supplementAug 18, 2026FDA
Nevro CorporationPMA supplementAug 15, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.